Verve Therapeutics to Participate in Upcoming Investor Conferences
Verve Therapeutics, a clinical-stage biotechnology company specializing in gene editing for cardiovascular disease, announced its participation in two upcoming investor conferences. Management will engage in fireside chats at the Jefferies Global Healthcare Conference on June 6, 2024, at 1 p.m. ET in New York, NY, and the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024, at 8 a.m. ET in Miami Beach, FL. Live webcasts of these events will be available on the company's website and will remain accessible for 30 days post-event.
- Verve Therapeutics is actively engaging with investors through high-profile conferences.
- Participation in the Jefferies Global Healthcare Conference exposes Verve to a wide range of potential investors.
- Presence at the Goldman Sachs 45th Annual Global Healthcare Conference enhances the company's visibility and credibility.
- Live webcasts provide broader access to the company's presentations and strategies.
- No new clinical or financial updates provided in the press release.
- The announcement does not include any significant business developments or new partnerships.
BOSTON, May 30, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that management will participate in fireside chats during the following investor conferences:
- Jefferies Global Healthcare Conference on Thursday, June 6, 2024, at 1 p.m. ET in New York, NY
- Goldman Sachs 45th Annual Global Healthcare Conference on Monday, June 10, 2024, at 8 a.m. ET in Miami Beach, FL
Live webcasts will be available in the investor section of the company's website at www.vervetx.com, and will be archived for 30 days following the fireside chats.
About Verve Therapeutics
Verve Therapeutics, Inc. (Nasdaq: VERV) is a clinical-stage genetic medicines company pioneering a new approach to the care of cardiovascular disease, potentially transforming treatment from chronic management to single-course gene editing medicines. The company’s lead programs – VERVE-101, VERVE-102, and VERVE-201 – target genes that have been extensively validated as targets for lowering low-density lipoprotein cholesterol (LDL-C), a root cause of atherosclerotic cardiovascular disease (ASCVD). VERVE-101 and VERVE-102 are designed to permanently turn off the PCSK9 gene in the liver and are being developed initially for heterozygous familial hypercholesterolemia (HeFH) and ultimately to treat patients with established ASCVD who continue to be impacted by high LDL-C levels. VERVE-201 is designed to permanently turn off the ANGPTL3 gene in the liver and is initially being developed for homozygous familial hypercholesterolemia (HoFH) and for refractory hypercholesterolemia where patients still have high LDL-C despite treatment with maximally-tolerated standard of care therapies. For more information, please visit www.VerveTx.com.
Investor Contact
Jen Robinson
Verve Therapeutics, Inc.
jrobinson@vervetx.com
Media Contact
Ashlea Kosikowski
1AB
ashlea@1abmedia.com
FAQ
When will Verve Therapeutics participate in the Jefferies Global Healthcare Conference?
When is Verve Therapeutics presenting at the Goldman Sachs 45th Annual Global Healthcare Conference?
Where can I watch the live webcasts of Verve Therapeutics' fireside chats?
How long will the webcasts of Verve Therapeutics' investor conference presentations be available?
What is Verve Therapeutics' focus in biotechnology?
